Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...

The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press release from ...

Viridian Therapeutics (VRDN) announced that the FDA has accepted the biologics license application for veligrotug for the treatment of thyroid eye ...

ArgenxARGX stock toppled Monday after the biotech scrapped plans to develop its blockbuster drug, Vyvgart, for an autoimmune ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to question ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

Viridian Therapeutics focuses on precision-driven biological research targeting rare and complex autoimmune conditions.

Learn more about whether Viridian Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.